首页> 外文期刊>Cancer Medicine >Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017
【24h】

Management and risk factors of recurrent gestational trophoblastic neoplasia: An update from 2004 to 2017

机译:复发性孕孕孕产性肿瘤的管理与危险因素:2004年至2017年的更新

获取原文
           

摘要

Objective We investigated the clinical characteristics, treatments, and survival of patients with gestational trophoblastic neoplasia (GTN) who experienced recurrence. Factors predictive of recurrence were also investigated. Methods Patients with GTN who recurred after completing chemotherapy at Peking Union Medical College Hospital Trophoblastic Disease Center were identified between January 2004 and December 2017. Logistic regression analysis was used to identify factors predictive of GTN recurrence. Results A total of 1827 patients with GTN achieved complete remission (CR) at our center, of whom 118 (6.5%) experienced recurrence during follow‐up. The recurrence rates for patients initially treated at our center and those referred to us were 2.7% and 14.6%, respectively. The majority of recurrent patients received floxuridine‐based multiagent chemotherapy (n?=?64). Patients who underwent surgery achieved a significantly higher CR rate than those who did not (88.6% vs 61.1%, P?=?.001). Although 94.1% of recurrent patients reachieved CR, 33.3% of them recurred for a second time. The 5‐year survival rate of the entire cohort was 80.4%. An interval between antecedent pregnancy and chemotherapy 12?months (OR: 6.600, 95% CI [3.217‐13.540], P??.001), and an interval from first chemotherapy to achieving β‐human chorionic gonadotropin (β‐hCG) normalization 14?weeks (OR: 2.226, 95% CI [1.080‐4.588], P?=?.030) were predictors of recurrence. Conclusions Patients with recurrent GTN are prone to recurring for a second time. Surgery plays a beneficial role in the management of recurrent GTN. An interval between antecedent pregnancy and chemotherapy 12?months, and an interval from first chemotherapy to achieving β‐hCG normalization 14?weeks were predictors of recurrence.
机译:目的我们研究了经历复发的妊娠期滋养细胞瘤形成(GTN)患者的临床特征,治疗和存活。还研究了预测的因素。方法在2004年1月至2017年1月期间在北京联合医院医院滋养滋养疾病疾病疾病疾病疾病疾病疾病疾病患有GTN患者。逻辑回归分析用于识别GTN复发的因素。结果共有1827例GTN患者在我们的中心实现了完整的缓解(CR),其中118名(6.5%)在随访期间经历了复发。在我们的中心初期治疗的患者的复发率分别为2.7%和14.6%。大多数复发患者接受了基于氟藻胺的多合理化疗(n?= 64)。接受手术的患者比没有(88.6%与61.1%,P?= 001)的CR率明显更高的CR率。虽然94.1%的复发性患者解放出CR,其中33.3%重复第二次。整个队列的5年生存率为80.4%。先前妊娠和化疗之间的间隔> 12?月(或:6.600,95%CI [3.217-13.540],p?<= 001),以及从第一次化疗到实现β-人绒毛膜促性腺激素(β-HCG)的间隔)正常化> 14周(或:2.226,95%CI [1.080-4.588],p?= 030)是复发的预测因素。结论患有复发性GTN的患者暂时重新出现第二次。手术在经常性GTN的管理中发挥着有益作用。前一种妊娠和化疗之间的间隔> 12?月,以及从第一次化疗到实现β-HCG标准化的间隔> 14个周是复发的预测因子。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号